All Updates

All Updates

icon
Filter
M&A
Illumina acquires Fluent BioSciences for undisclosed amount to enhance single-cell analysis capabilities
Precision Medicine
Jul 9, 2024
This week:
Partnerships
MGI Tech and Predica Diagnostics collaborate to develop Predica's targeted RNA sequencing tests
Precision Medicine
Yesterday
Partnerships
Renalytix partners with Steno Diabetes Center to advance precision medicine solutions for diabetes and chronic kidney disease
Precision Medicine
Yesterday
Partnerships
Myriad Genetics and Personalis cross-license patents for tumor-informed cancer treatment tests
Precision Medicine
Yesterday
Funding
Element Biosciences raises USD 277 million in Series D funding to commercialize AVITI DNA sequencer and support AVITI24 launch
Precision Medicine
Yesterday
Funding
Jacobi Robotics raises USD 5 million in seed funding to expand capacity
Smart Factory
Yesterday
M&A
Formlabs acquires Micronics for undisclosed sum to develop next-generation SLS printers
Additive Manufacturing
Yesterday
Partnerships
Anthropic partners with Amazon Bedrock to fine-tune Claude 3 Haiku model
Foundation Models
Yesterday
Funding
Lemon.markets raises EUR 12 million in funding to support growth
FinTech Infrastructure
Yesterday
M&A
Kipu Quantum acquires PlanQK platform to enhance accessibility to quantum computing solutions
Quantum Computing
Yesterday
Partnerships
Quantinuum and STFC Hartree Centre partner to enhance quantum computing accessibility in UK
Quantum Computing
Yesterday
Precision Medicine

Precision Medicine

Jul 9, 2024

Illumina acquires Fluent BioSciences for undisclosed amount to enhance single-cell analysis capabilities

M&A

  • Illumina has acquired Fluent BioSciences to support its preparations for single-cell research. The acquisition was closed on July 9, 2024. Financial details of the transaction were not disclosed.

  • Post-acquisition, Illumina plans to improve its sequencing and informatics solutions by integrating Fluent's PIPseq V into its product portfolio to develop full end-to-end solutions for single-cell analysis. The company also plans to continue its existing partnerships in single-cell research by providing an open NGS platform that allows researchers to choose the tools suitable for their needs.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.